ERBB2 and breast cancer: The mechanisms of resistance and sensitivity to anti-HER2 therapies in HER2-positive BC have been thoroughly investigated and reported [12,13,14], however, in this context little is known about the role of HER2 heterogeneity defined by ISH [15,16].